- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03371537
Study of Hemodynamic Conditions Measured During Hepatectomy (DEBIFOIE)
Hepatocellular insufficiency is a dreaded complication after hepatectomy, since, if it is persistent, it leads to the death of the patient in the absence of liver transplantation.
The preoperative evaluation aims in particular to estimate the risk of postoperative hepatocellular insufficiency so as to minimize or contraindicate high-risk patients.
It has been shown that the flow of the portal vein is correlated with liver function, especially in the living donor and after portal embolization. More recently, the study of flow rates in the portal vein and the hepatic artery after transplantation has shown a correlation with the recovery of graft function.
The hypothesis is that portal and arterial flow after hepatectomy can predict postoperative hepatocellular function.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Tours, France, 37044
- Service de Chirurgie Digestive, Oncologique, Endocrinienne et Transplantation Hépatique, CHRU de TOURS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- patient 18 years or more
- Patient undergoing laparotomy for liver resection
Exclusion Criteria:
- Patient under tutorship or curatorship
- Pregnant or lactating woman
- Difficulties in understanding French
- Patient operated by laparoscopy
- Patient having objected to the processing of his data
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Hepatectomy
Patient undergoing laparotomy for liver resection.
The aim is to measure the flow rates in the portal vein and the hepatic artery.
|
Mesure of liver debit during hepatectomy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Liver vessel debit
Time Frame: Baseline
|
Mesure of liver debit during hepatectomy
|
Baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ephrem SALAME, MD-PhD, University Hospital, Tours
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RIPH3-RNI17/DEBIFOIE
- 2017-61 (CPP)
- 2017-A01754-49 (Other Identifier: IdRCB)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Dysfunction
-
HRI-MAIL-NITEnrolling by invitationMASLD | Metabolic Dysfunction-Associated Steatotic Liver Disease | MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease | MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis) | MetALDUnited States
-
Consorcio Centro de Investigación Biomédica en...Hospital General Universitario Gregorio Marañon; Universidad Complutense de... and other collaboratorsNot yet recruitingLiver Fibrosis/NASH | MASH - Metabolic Dysfunction-Associated Steatohepatitis | MASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseSpain
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompleted
-
University Medical Centre LjubljanaEnrolling by invitationLiver Transplantation | Tissue Metabolism | Liver Graft DysfunctionSlovenia
-
Loma Linda UniversityWithdrawnLiver Graft Dysfunction
-
National Cancer Institute (NCI)Completed
-
Endra LifesciencesRecruitingFatty Liver Disease, Nonalcoholic | MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)United States
-
Beijing Friendship HospitalFudan University; Ruijin Hospital; Xinhua Hospital, Shanghai Jiao Tong University... and other collaboratorsNot yet recruitingMetabolic Dysfunction-associated Steatohepatitis (MASH) | Metabolic Dysfunction Associated Steatotic Liver DiseaseChina
-
University of AthensCompleted
-
Taipei City HospitalNational Yang Ming UniversityCompletedLiver DysfunctionTaiwan
Clinical Trials on Liver debit measure
-
Harvard Medical School (HMS and HSDM)University of Michigan; Brigham and Women's Hospital; Harvard UniversityActive, not recruitingHealth Care Utilization | Health Care CostsUnited States
-
Harvard Medical School (HMS and HSDM)Brigham and Women's HospitalActive, not recruitingPregnancy Related | Miscarriage | Maternal Care PatternsUnited States
-
Harvard Medical School (HMS and HSDM)Brigham and Women's Hospital; Cambridge Health AllianceCompleted
-
Instituto Ecuatoriano de Enfermedades DigestivasCompleted
-
University Hospital, ToulouseCompleted
-
Assistance Publique - Hôpitaux de ParisRecruitingRespiratory; Disorder, Functional, ImpairedFrance
-
University of Geneva, SwitzerlandRecruitingPregnancy Related | Cardiac OutputSwitzerland
-
Assistance Publique Hopitaux De MarseilleUnknown
-
Roswell Park Cancer InstituteNational Institutes of Health (NIH)Completed
-
University of FloridaWithdrawnAortic Stenosis | Transcatheter Aortic Valve Replacement | Glutathione Peroxidase ActivityUnited States